Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

Bibliography

• JMEbos, RSKerbel. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210–21
   PubMed Web of Science ®Google Scholar
• JMLlovet, SRicci, VMazzaferro, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90
   PubMed Web of Science ®Google Scholar
• BEscudier, TEisen, WMStadler, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34
   PubMed Web of Science ®Google Scholar
• MSBrose, CMNutting, BJarzab, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319–28
   PubMed Web of Science ®Google Scholar
• ARowland, JOMiners, PIMackenzie. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013;45:1121–32
   PubMed Web of Science ®Google Scholar
• JMagdalou, SFournel-Gigleux, MOuzzine. Insights on membrane topology and structure/function of UDP-glucuronosyltransferases. Drug Metab Rev 2010;42:159–66
   PubMed Web of Science ®Google Scholar
• AThomas-Schoemann, BBlanchet, CBardin, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014;89:179–96
   PubMed Web of Science ®Google Scholar
• GLRosner, JCPanetta, FInnocenti, et al. Pharmacogenetic pathway analysis of irinotecan. Clin Pharmacol Ther 2008;84:393–402
   PubMed Web of Science ®Google Scholar
• NPvan Erp, HGelderblom, HJGuchelaar. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692–706
   PubMed Web of Science ®Google Scholar
• JZhang, PLYang, NSGray. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28–39
   PubMed Web of Science ®Google Scholar
• HJKlumpen, CFSamer, RHMathijssen, et al. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 2011;37:251–60
   PubMed Web of Science ®Google Scholar
• CLBello, LSherman, JZhou, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006;17:353–8
   PubMed Web of Science ®Google Scholar
• NWidmer, CBardin, EChatelut, et al. Review of therapeutic drug monitoring of anticancer drugs part two – targeted therapies. Eur J Cancer 2014;50:2020–36
   PubMed Web of Science ®Google Scholar
• KMKoch, NJReddy, RBCohen, et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009;27:1191–6
   PubMed Web of Science ®Google Scholar
• EIHeath, EGChiorean, CJSweeney, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:818–23
   PubMed Web of Science ®Google Scholar
• CYoo, MHRyu, BWKang, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010;28:1554–9
   PubMed Web of Science ®Google Scholar
• MHornecker, BBlanchet, BBillemont, et al. Saturable absorption of sorafenib in patients with solid tumors: a population model. Invest New Drugs 2012;30:1991–2000
   PubMed Web of Science ®Google Scholar
• CYLu, YSYeh, CWHuang, et al. Folfiri and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 2014;7:2143–6
   PubMed Web of Science ®Google Scholar
• PBoudou-Rouquette, CNarjoz, JLGolmard, et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 2012;7:e42875
   PubMed Web of Science ®Google Scholar
• YChen, MATortorici, MGarrett, et al. Clinical pharmacology of axitinib. Clin Pharmacokinet 2013;52:713–25
   PubMed Web of Science ®Google Scholar
• BGao, SYeap, AClements, et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 2012;30:4017–25
   PubMed Web of Science ®Google Scholar
• BPeng, PLloyd, HSchran. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–94
   PubMed Web of Science ®Google Scholar
• KMSakamoto. Su-11248 sugen. Curr Opin Investig Drugs 2004;5:1329–39
   PubMedGoogle Scholar
• GMKeating, ASantoro. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223–40
   PubMed Web of Science ®Google Scholar
• PBorst, ROElferink. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537–92
   PubMed Web of Science ®Google Scholar
• RLOostendorp, JHBeijnen, JHSchellens. The biological and clinical role of drug transporters at the intestinal barrier. Cancer Treat Rev 2009;35:137–47
   PubMed Web of Science ®Google Scholar
• ABrozik, CHegedus, ZErdei, et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? Expert Opin Drug Metab Toxicol 2011;7:623–42
   PubMed Web of Science ®Google Scholar
• CGDa Silva, RJHoneywell, HDekker, et al. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters. Expert Opin Drug Metab Toxicol 2015;1–15. [Epub ahead of print]
   Google Scholar
• ACTutulan-Cunita, MMikoshi, MMizunuma, et al. Mutational analysis of the yeast multidrug resistance ABC transporter PDR5P with altered drug specificity. Genes Cells 2005;10:409–20
   PubMed Web of Science ®Google Scholar
• PDi Gion, FKanefendt, ALindauer, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 2011;50:551–603
   PubMed Web of Science ®Google Scholar
• SJHotte, HWHirte. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249–53
   PubMed Web of Science ®Google Scholar
• MTod, OMir, NBancelin, et al. Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients. Pharm Res 2011;28:3199–207
   PubMed Web of Science ®Google Scholar
• CGomo, RCoriat, LFaivre, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs 2011;29:1511–14
   PubMed Web of Science ®Google Scholar
• SNoda, MShioya, DHira, et al. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma. Cancer Chemother Pharmacol 2013;72:269–72
   PubMed Web of Science ®Google Scholar
• CLathia, JLettieri, FCihon, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006;57:685–92
   PubMed Web of Science ®Google Scholar
• DStrumberg, JWClark, AAwada, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426–37
   PubMed Web of Science ®Google Scholar
• SWilhelm, DSChien. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255–7
   PubMed Web of Science ®Google Scholar
• BSwift, NNebot, JKLee, et al. Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos 2013;41:1179–86
   PubMed Web of Science ®Google Scholar
• CJPeer, TMSissung, AKim, et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 2012;18:2099–107
   PubMed Web of Science ®Google Scholar
• SHu, ZChen, RFranke, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009;15:6062–9
   PubMed Web of Science ®Google Scholar
• EIZimmerman, SHu, JLRoberts, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013;19:1458–66
   PubMed Web of Science ®Google Scholar
• SHu, RHMathijssen, Pde Bruijn, et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 2014;110(4):894–8
   PubMed Web of Science ®Google Scholar
• JSLagas, RAvan Waterschoot, RWSparidans, et al. Breast cancer resistance protein and p-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther 2010;9:319–26
   PubMed Web of Science ®Google Scholar
• SAgarwal, RSane, JROhlfest, et al. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011;336:223–33
   PubMed Web of Science ®Google Scholar
• YWei, YMa, QZhao, et al. New use for an old drug: inhibiting ABCG2 with sorafenib. Mol Cancer Ther 2012;11:1693–702
   PubMed Web of Science ®Google Scholar
• KMross, AFrost, SSteinbild, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012;18:2658–67
   PubMed Web of Science ®Google Scholar
• EGupta, TMLestingi, RMick, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994;54:3723–5
   PubMed Web of Science ®Google Scholar
• EWasserman, AMyara, FLokiec, et al. Severe CPT-11 toxicity in patients with Gilbert’s syndrome: two case reports. Ann Oncol 1997;8:1049–51
   PubMed Web of Science ®Google Scholar
• LIyer, DHall, SDas, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999;65:576–82
   PubMed Web of Science ®Google Scholar
• RIacovelli, APalazzo, GProcopio, et al. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2014;77:929–38
   PubMed Web of Science ®Google Scholar
• KSOgle, GMSwanson, NWoods, et al. Cancer and comorbidity: redefining chronic diseases. Cancer 2000;88:653–63
   PubMed Web of Science ®Google Scholar
• SAntoun, VEBaracos, LBirdsell, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594–8
   PubMed Web of Science ®Google Scholar
• OMir, RCoriat, BBlanchet, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012;7:e37563
   PubMed Web of Science ®Google Scholar
• SJCushen, DGPower, MYTeo, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• OHuillard, OMir, MPeyromaure, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034–41
   PubMed Web of Science ®Google Scholar
• Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii21–6
   PubMed Web of Science ®Google Scholar
• JArrondeau, OMir, PBoudou-Rouquette, et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2012;30:2046–9
   PubMed Web of Science ®Google Scholar